Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

March 27, 2026

Vol.52 No.12

By Richard M. Goldberg

Beyond the lab: Engineering collaboration in modern cancer research

Cancer research increasingly demands environments that mirror the biology it seeks to understand: Complex, adaptive and deeply interconnected. At Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, collaboration is not treated as an optional cultural trait but as a structural requirement.

March 27, 2026

Vol.52 No.12

Funding Opportunities

SITC seeks applications for two fellowships

Applications are now being accepted for the Society for Immunotherapy of Cancer fellowship opportunities. This year, SITC is offering two fellowships totaling $150,000 in funding.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

A computational tool infers changes occurring at the ends of the chromosomes housing our DNA, which it does so by detecting structural alterations in cells and tissues captured in images taken of routine medical biopsies, according to a study by scientists at Sanford Burnham Prebys Medical Discovery Institute.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Computational biology tool automates and standardizes genome sequencing analysis, Sanford Burnham study finds

In a single experiment, scientists can decipher the entire genomes of many patient samples, animal models, or cultured cells. To fully realize the potential to study biology at this scale, researchers must be equipped to analyze the titanic troves of data generated by these new methods.

March 20, 2026

Vol.52 No.11

Conversation with The Cancer Letter

Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”

Five years ago, Tyler Jacks took on a new challenge, becoming president of Break Through Cancer, a foundation that has pledged to spend at least $500 million to support research projects across top tier cancer centers.

March 13, 2026

Vol.52 No.10

By Paul Goldberg

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

YOU MAY BE INTERESTED IN

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

Beyond the lab: Engineering collaboration in modern cancer research

SITC seeks applications for two fellowships

Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

Computational biology tool automates and standardizes genome sequencing analysis, Sanford Burnham study finds

Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”

Renew today!

Subscriber content

Never miss an issue!

Login

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

YOU MAY BE INTERESTED IN

In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt

Beyond the lab: Engineering collaboration in modern cancer research

SITC seeks applications for two fellowships

Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

Computational biology tool automates and standardizes genome sequencing analysis, Sanford Burnham study finds

Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”

Never miss an issue!

Login

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt